// App-Quantinova.ai

266 : Tumour mutation burden (TMB) and efficacy outcomes in the phase III DANUBE study of advanced urothelial carcinoma (UC)

Researchers

Presenter

  • Sophie Wildsmith

Principal Investigators

  • Jill Walker

  • Anne LHernault

  • Weimin Li

  • Hannah Bye

  • Philip He

  • Feng Xiao

  • Qu Zhang

  • Ross Stewart

  • Melissa de los Reyes

  • Rajiv Raja

  • Wendy Levin

  • Ashok Gupta

  • Thomas Powles

  • Joaquim Bellmunt

  • Matthew Galsky

  • Alexandra Drakaki

  • Michiel van der Heijden

Medical Centers

  • AstraZeneca, Cambridge, MA

  • Barts Cancer Institute, QMUL, London, UK

  • Harvard Medical School, Boston, MA

  • University of Southern California, Los Angeles, CA

  • Netherlands Cancer Institute (NKI), Amsterdam, Netherlands

Locations

  • United Kingdom

  • United States

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Advanced Urothelial Carcinoma

Biomarkers

  • Tumor mutational burden

Drug/Treatment

  • Ticilimumab

  • Durvalumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved